- Home
- GRI vs SGBX Comparison
GRI vs SGBX Comparison
Compare GRI & SGBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- SGBX
- Stock Information
- Founded
- GRI 2018
- SGBX 2007
- Country
- GRI United States
- SGBX United States
- Employees
- GRI N/A
- SGBX N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- SGBX RETAIL: Building Materials
- Sector
- GRI Health Care
- SGBX Consumer Discretionary
- Exchange
- GRI Nasdaq
- SGBX Nasdaq
- Market Cap
- GRI 3.2M
- SGBX 2.7M
- IPO Year
- GRI N/A
- SGBX 2017
- Fundamental
- Price
- GRI $1.35
- SGBX $0.66
- Analyst Decision
- GRI Strong Buy
- SGBX
- Analyst Count
- GRI 2
- SGBX 0
- Target Price
- GRI $22.00
- SGBX N/A
- AVG Volume (30 Days)
- GRI 110.6K
- SGBX 1.4M
- Earning Date
- GRI 08-13-2025
- SGBX 06-13-2025
- Dividend Yield
- GRI N/A
- SGBX N/A
- EPS Growth
- GRI N/A
- SGBX N/A
- EPS
- GRI N/A
- SGBX N/A
- Revenue
- GRI N/A
- SGBX $4,574,857.00
- Revenue This Year
- GRI N/A
- SGBX $1,628.82
- Revenue Next Year
- GRI N/A
- SGBX N/A
- P/E Ratio
- GRI N/A
- SGBX N/A
- Revenue Growth
- GRI N/A
- SGBX N/A
- 52 Week Low
- GRI $1.10
- SGBX $0.30
- 52 Week High
- GRI $43.69
- SGBX $2.95
- Technical
- Relative Strength Index (RSI)
- GRI 41.49
- SGBX 45.91
- Support Level
- GRI $1.20
- SGBX $0.60
- Resistance Level
- GRI $1.35
- SGBX $0.97
- Average True Range (ATR)
- GRI 0.10
- SGBX 0.12
- MACD
- GRI 0.02
- SGBX -0.03
- Stochastic Oscillator
- GRI 37.60
- SGBX 22.17
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About SGBX Safe & Green Holdings Corp.
Safe & Green Holdings Corp is a modular solutions company. The company currently provides modules made out of both code-engineered cargo shipping containers and wood for use as both permanent or temporary structures for residential housing use and commercial use, including for health care facilities. It operates in four segments: construction services; medical; real estate development; and environmental. The company generates the majority of its revenue from the Construction segment includes the company's manufacturing unit SG ECHO and other modules projects.